Corvus Pharmaceuticals Inc.
CRVS | NASDAQ
$13.03
+$0.61 (+4.91%)
Sep 22, 2026, 11:09 AM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 29K | 26K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | -29K | -26K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -19.3M | -14.88M | -12.22M | -10.57M | -10.26M | -9.92M | -8.11M | -7.26M | -5.94M | -6.25M | -5.65M | -5.56M | -5.62M | -6.57M | -5.67M | -12.47M | -7.01M | -7.41M | -6.81M | -9.05M | -11.29M | -11.48M |
Interest Income | n/a | n/a | -1.9M | 738K | 639K | 525K | 508K | 566K | 434K | 316K | 380K | 425K | 403K | 376K | 318K | 225K | 100K | 11K | n/a | n/a | 1K | 3K |
Pretax Income | -17.25M | -13.69M | -12.32M | -10.16M | -8M | 15.19M | -12.11M | -40.22M | -4.26M | -5.7M | -6.65M | -6M | -6.5M | -7.87M | -9.82M | -14.83M | -8.36M | -8.3M | -9.24M | -10.67M | -11.75M | -11.58M |
Net Income | -17.96M | -13.69M | -12.32M | -10.16M | -8M | 15.19M | -12.11M | -40.22M | -4.26M | -5.7M | -6.65M | -6M | -6.5M | -7.87M | -9.82M | -14.83M | -8.36M | -8.3M | -9.24M | -10.67M | -11.75M | -11.58M |
Selling & General & Admin | 3.33M | 3.7M | 2.28M | 2.12M | 2.39M | 2.47M | 2.13M | 2.03M | 1.82M | 2.18M | 1.65M | 1.6M | 1.65M | 1.98M | 1.59M | 2.11M | 2.09M | 2.31M | 2.02M | 2.06M | 2.18M | 3.25M |
Research & Development | 15.96M | 11.18M | 9.94M | 8.45M | 7.87M | 7.45M | 5.97M | 5.22M | 4.11M | 4.08M | 4M | 3.97M | 3.97M | 4.59M | 4.08M | 10.37M | 4.92M | 5.1M | 4.79M | 6.99M | 9.11M | 8.23M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 19.3M | 14.88M | 12.19M | 10.57M | 10.26M | 9.92M | 8.11M | 7.26M | 5.94M | 6.25M | 5.65M | 5.56M | 5.62M | 6.57M | 5.67M | 12.47M | 7.01M | 7.41M | 6.81M | 9.05M | 11.29M | 11.48M |
Interest Expense | n/a | 1.78M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 8K | 11K | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 19.3M | 14.88M | 12.22M | 10.57M | 10.26M | 9.92M | 8.11M | 7.26M | 5.94M | 6.25M | 5.65M | 5.56M | 5.62M | 6.57M | 5.67M | 12.47M | 7.01M | 7.41M | 6.81M | 9.05M | 11.29M | 11.48M |
Income Tax Expense | 709K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 92.37M | 90M | 78.96M | 82.84M | 77.77M | 72.13M | 68.35M | 66.7M | 59.71M | 49.04M | 49.04M | 48.97M | 47.5M | 46.56M | 46.55M | 46.55M | 46.55M | 46.55M | 46.55M | 43.95M | 42.25M | 34.52M |
Shares Outstanding (Diluted) | 92.37M | 90M | 79.74M | 82.84M | 77.77M | 75.15M | 68.35M | 66.7M | 59.71M | 49.04M | 49.04M | 48.97M | 47.5M | 46.56M | 46.55M | 46.55M | 46.55M | 46.55M | 46.55M | 43.95M | 42.25M | 34.52M |
EPS (Basic) | -0.19 | -0.15 | -0.18 | -0.12 | -0.10 | 0.21 | -0.18 | -0.60 | -0.07 | -0.12 | -0.14 | -0.12 | -0.14 | -0.17 | -0.21 | -0.32 | -0.18 | -0.18 | -0.20 | -0.24 | -0.28 | -0.34 |
EPS (Diluted) | -0.19 | -0.15 | -0.18 | -0.12 | -0.10 | -0.13 | -0.18 | -0.60 | -0.07 | -0.12 | -0.14 | -0.12 | -0.14 | -0.17 | -0.21 | -0.32 | -0.18 | -0.18 | -0.20 | -0.24 | -0.28 | -0.34 |
EBITDA | -17.19M | -11.88M | -12.3M | -10.13M | -7.97M | 15.22M | -12.09M | -40.2M | -4.24M | -5.68M | -6.63M | -5.97M | -6.47M | -7.82M | -9.72M | -14.74M | -8.27M | -8.21M | -9.14M | -10.55M | -11.63M | -11.35M |
EBIT | -17.25M | -11.91M | -12.32M | -10.16M | -8M | 15.19M | -12.11M | -40.22M | -4.26M | -5.7M | -6.65M | -6M | -6.5M | -7.87M | -9.82M | -14.83M | -8.36M | -8.3M | -9.23M | -10.66M | -11.75M | -11.48M |
Depreciation & Amortization | 63K | 29K | 26K | 28K | 29K | 22K | 20K | 21K | 21K | 23K | 28K | 30K | 36K | 57K | 94K | 94K | 92K | 87K | 93K | 108K | 122K | 137K |
Add to Watchlist
Select watchlists to add or remove CRVS